Authors' response to ‘Aspirin dose for treatment of Kawasaki disease’

about

Cutaneous Manifestations of Medium- and Large-Vessel Vasculitis.

P2860

Q39331967-0297BD95-0A30-4BD3-ADF7-9F5CDC824790

P2860

Authors' response to ‘Aspirin dose for treatment of Kawasaki disease’

Item

http://www.wikidata.org/entity/Q58809663

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2014

@uk

name

Authors' response to ‘Aspirin dose for treatment of Kawasaki disease’

@en

Authors' response to ‘Aspirin dose for treatment of Kawasaki disease’

@nl

type

Item

label

Authors' response to ‘Aspirin dose for treatment of Kawasaki disease’

@en

Authors' response to ‘Aspirin dose for treatment of Kawasaki disease’

@nl

prefLabel

Authors' response to ‘Aspirin dose for treatment of Kawasaki disease’

@en

Authors' response to ‘Aspirin dose for treatment of Kawasaki disease’

@nl

P1476

Authors' response to 'aspirin dose for treatment of Kawasaki disease'

@en

P2093

Delane Shingadia

http://www.w3.org/2001/XMLSchema#string

Despina Eleftheriou

http://www.w3.org/2001/XMLSchema#string

Michael Levin

http://www.w3.org/2001/XMLSchema#string

Nigel Klein

http://www.w3.org/2001/XMLSchema#string

Paul Brogan

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis, treatment, and long-term management of Kawasaki disease

Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research

Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome

Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease

Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.

Is high-dose aspirin necessary in the acute phase of kawasaki disease?

Management of Kawasaki disease.

Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.

A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.

Reye's syndrome and aspirin. Evidence for a dose-response effect.

P304

300-301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARCHDISCHILD-2014-307798

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Robert M. Tulloh

P577

2014-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25425602

http://www.w3.org/2001/XMLSchema#string

P921

aspirin

Authors' response to ‘Aspirin dose for treatment of Kawasaki disease’

about

P2860

P2860

Authors' response to ‘Aspirin dose for treatment of Kawasaki disease’

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921